SS Innovations International (NASDAQ: SSII) will showcase its SSi Mantra surgical robotic system at the Society of Robotic Surgery (SRS) 2026 Annual Meeting, scheduled for July 23-26 in Hollywood, Florida. The event, one of the largest annual gatherings of robotic surgery specialists, will feature the SSi Mantra in multiple technical sessions, including a live telesurgery broadcast from India demonstrating remote surgical capabilities. This presentation highlights the company's expanding clinical experience and strategic focus on telesurgery, a field with significant implications for global healthcare access.
The SSi Mantra system has been used in over 12,375 procedures as of July 6, 2026, spanning cardiac, pediatric, and telesurgical applications. Approximately 2,100 physicians have been trained on the platform, which has been utilized across more than 170 different surgical procedures. These metrics indicate rapid adoption and growing confidence in the system's versatility and reliability. The live telesurgery, a partial nephrectomy performed remotely from India, will demonstrate the platform's ability to overcome geographic barriers, potentially enabling specialist care in underserved regions.
Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, will participate in multiple conference presentations covering telesurgery, robotic surgery adoption, and regulatory developments. His involvement underscores the company's thought leadership in advancing surgical robotics. The SRS meeting provides a platform for SS Innovations to engage with key opinion leaders and potential partners, further driving adoption of the SSi Mantra system.
The implications of this announcement are multifaceted. First, the live telesurgery demonstration validates the SSi Mantra's remote capabilities, positioning it as a tool for expanding surgical access globally. Second, the substantial number of procedures and trained physicians suggests the system is gaining traction in a competitive market dominated by established players. Third, the focus on regulatory developments indicates SS Innovations is actively navigating approval pathways, which could accelerate commercial expansion into new regions.
For healthcare providers, the SSi Mantra offers a cost-effective alternative to existing robotic systems, with potential for reduced procedure costs and improved patient outcomes. The telesurgery capability could revolutionize surgical training and enable remote proctoring, addressing workforce shortages in specialized fields. Investors should note that the company's progress in clinical adoption and regulatory milestones could drive future growth. However, forward-looking statements in the announcement caution that actual results may differ due to risks outlined in SEC filings.
More information about the SSi Mantra and SS Innovations can be found in the company's newsroom at https://ibn.fm/SSII. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
